A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Go Back to All Clinical Trials

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Brief description of study

Clinical Study Identifier: s22-01005

ClinicalTrials.gov Identifier: NCT05384626

Principal Investigator: Sally Lau.

Other Investigators: Samantha VanMaanen, Carol M Lee, Salman Rafi Punekar, Elaine Shum, Jessica Wang, Jonathan B Kahn, Gabrielle Fridman, Joshua K Sabari, David Mendoza, Melissa L Martinez, Vamsidhar Velcheti, Natalia Cherkassky, Kirby Rodriguez.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies